Immunological memory is thought to depend on a stem cell–like, self-renewing population of
lymphocytes capable of differentiating into effector cells in response to antigen re-exposure …

Homozygosity for the naturally occurring Δ32 deletion in the HIV co-receptor CCR5 confers
resistance to HIV-1 infection. We generated an HIV-resistant genotype de novo using …

Persistence of T cells engineered with chimeric antigen receptors (CARs) has been a major
barrier to use of these cells for molecularly targeted adoptive immunotherapy. To address …

Mesothelin is a cell-surface molecule over-expressed on a large fraction of carcinomas, and
thus is an attractive target of immunotherapy. A molecularly targeted therapy for these …

Purpose: Adoptive T-cell immunotherapy with tumor infiltrating lymphocytes or genetically-
modified T cells has yielded dramatic results in some cancers. However, T cells need to …

Redirecting T lymphocyte antigen specificity by gene transfer can provide large numbers of
tumor-reactive T lymphocytes for adoptive immunotherapy. However, safety concerns …

With the notable exception of B-cell malignancies, the efficacy of chimeric antigen receptor
(CAR) T cells has been limited, and CAR T cells have not been shown to expand and persist …

Human T cells engineered to express a chimeric antigen receptor (CAR) specific for folate
receptor-α (FRα) have shown robust antitumor activity against epithelial cancers in vitro but …

Cell therapy is poised to play an enormous role in regenerative medicine. However, little
guidance is being made available to academic and industrial entities in the start-up phase …

Abemaciclib, an inhibitor of cyclin dependent kinases 4 and 6 (CDK4/6), has recently been
approved for the treatment of hormone receptor-positive breast cancer. In this study, we use …